Compare Infosys Limited (INFY) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Tempus AI — how do they compare? Infosys Limited trades at $10.74 (market cap $41.74B), while Tempus AI trades at $70.95 (market cap $12.58B). The key difference: Infosys Limited is far larger — about 3.3× Tempus AI's market cap, and Infosys Limited pays a 4.89% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Tempus AI for 23 Days on average.
| INFY | TEM | |
|---|---|---|
Market Cap | $41.74B | $12.58B |
Volume | 31,354,285 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.22 | $99.28 |
52-Week Low | $10.49 | $41.55 |
Typical Hold Time | 27 Days | 23 Days |
Enterprise Value | $39.48B | $13.21B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.75, up 1.9% in the last 24 hours, with a bearish technical signal from moving averages. The company reported a net income of $3.16B on $19.28B revenue for 2025, with profitability metrics like a 16.37% net margin and 32.12% ROE. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, to drive innovation. Earnings have been mixed, with beats in Q4 2025 and Q1 2026 but a miss in Q2 2026.
The outlook is cautious; while valuation ratios like a P/E of 13.21 appear reasonable and analyst consensus targets $11.48, weak IT spending and AI pricing pressure pose risks. Institutional sentiment is mixed with 35% buy ratings, but negative cash flow trends in 2026 forecast demand careful monitoring of execution against guidance.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
